Influence of a Vaccination Schedule on Viral Load Rebound and Immune Responses in Successfully Treated HIV-Infected Patients
- 1 December 2009
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 25 (12), 1249-1259
- https://doi.org/10.1089/aid.2009.0015
Abstract
Vaccination is recommended for HIV-infected patients. Transient increases of viral load (VL) and risk of developing resistance to HAART have been described. In addition, VL rebounds could increase HIV-specific immune responses. Twenty-six successfully treated HIV-infected adults were randomized to receive a vaccination schedule or placebo during 12 months. Afterward, HAART was discontinued. Influences of vaccination over VL, genotypic mutations, different T cell subsets, and HIV-1-specific immune responses were evaluated. Patients did not present any secondary effect. No differences in incidence of detectable VL determinations were detected between groups [relative risk 0.54 (95% CI 0.23-1.26)]. No relevant resistance mutations were detected. The vaccinated group showed a significant drop in CD4(+) T cells (p = 0.046) associated with increases in activated T cells. HIV-1-specific lymphoproliferative responses increased more in the vaccinated group during the vaccination period. Viral rebound dynamics after interrupting HAART were similar in both groups. A vaccination schedule in successfully treated HIV patients was safe, was not associated with an increase in detectable VL, and did not increase the risk of developing resistance mutations. However, it induced an increase in T cell activation and a drop in CD4(+) T cells, although these changes did not influence the VL rebound dynamics after HAART interruption.This publication has 51 references indexed in Scilit:
- Dynamics of T Cells Subsets and Lymphoproliferative Responses During Structured Treatment Interruption Cycles and After Definitive Interruption of HAART in Early Chronic HIV Type-1-Infected PatientsAIDS Research and Human Retroviruses, 2006
- Intermittent Episodes of Detectable HIV Viremia in Patients Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based or Protease Inhibitor-Based Highly Active Antiretroviral Therapy Regimens Are Equivalent in Incidence and PrognosisClinical Infectious Diseases, 2005
- Long-Term Follow-Up of Asymptomatic HIV-Infected Patients Who Discontinued Antiretroviral TherapyClinical Infectious Diseases, 2005
- Long-term Clinical Follow-up, without Antiretroviral Therapy, of Patients with Chronic HIV-1 Infection with Good Virological Response to Structured Treatment InterruptionClinical Infectious Diseases, 2004
- No Evidence of an Association between Transient HIV Viremia (“Blips”) and Lower Adherence to the Antiretroviral Medication RegimenThe Journal of Infectious Diseases, 2004
- Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patientsAIDS, 2003
- CD4+ T-cell depletion in HIV infection: Are we closer to understanding the cause?Nature Medicine, 2002
- Effect of Influenza Vaccination on Viral Replication and Immune Response in Persons Infected with Human Immunodeficiency Virus Receiving Potent Antiretroviral TherapyThe Journal of Infectious Diseases, 2000
- T cell activation and human immunodeficiency virus replication after influenza immunization of infected childrenThe Pediatric Infectious Disease Journal, 1996
- Cellular activation and human immunodeficiency virus infectionCurrent Opinion in Immunology, 1990